BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China · Delayed Price · Currency is CNY 92.73
+0.02 (0.02%)
At close: Sep 12, 2025
SHA:688166 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Operating Revenue | 1,142 | 1,248 | 1,161 | 1,013 | 1,050 | 783.71 | Upgrade |
Other Revenue | 20.37 | 34.27 | 18.34 | 4.04 | 2.25 | 1.67 | Upgrade |
| 1,162 | 1,283 | 1,180 | 1,017 | 1,052 | 785.38 | Upgrade | |
Revenue Growth (YoY) | -7.00% | 8.73% | 15.94% | -3.33% | 34.00% | 56.09% | Upgrade |
Cost of Revenue | 536.93 | 560.51 | 542.9 | 390.95 | 470.07 | 363.39 | Upgrade |
Gross Profit | 625.37 | 722.04 | 636.61 | 626.38 | 582.34 | 421.99 | Upgrade |
Selling, General & Admin | 225.82 | 210.87 | 180.46 | 184.98 | 145.56 | 99.04 | Upgrade |
Research & Development | 292.98 | 297.45 | 248.59 | 207.02 | 173.29 | 138.26 | Upgrade |
Other Operating Expenses | -2.67 | 1.39 | -1.59 | 5.22 | 4.22 | 2.4 | Upgrade |
Operating Expenses | 520.64 | 521.27 | 428.37 | 395 | 333.18 | 238.89 | Upgrade |
Operating Income | 104.73 | 200.76 | 208.24 | 231.38 | 249.16 | 183.11 | Upgrade |
Interest Expense | -53.89 | -52.44 | -44.42 | -23.71 | -9.7 | -2.04 | Upgrade |
Interest & Investment Income | 6.92 | 10.96 | 17.99 | 6.2 | 10.14 | 13.01 | Upgrade |
Currency Exchange Gain (Loss) | 0.09 | 1.92 | 2.6 | 12.99 | 4.63 | -11.02 | Upgrade |
Other Non Operating Income (Expenses) | 5.08 | -2.14 | -1.88 | -2.17 | -1.77 | -0.92 | Upgrade |
EBT Excluding Unusual Items | 62.92 | 159.07 | 182.54 | 224.68 | 252.46 | 182.13 | Upgrade |
Impairment of Goodwill | -4.38 | -4.38 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -13.03 | -17.33 | -15.26 | -3.39 | 0.79 | 0.04 | Upgrade |
Gain (Loss) on Sale of Assets | -0.14 | -0.15 | -0.25 | -0.01 | -0.26 | -0.27 | Upgrade |
Asset Writedown | -2.77 | - | - | - | - | - | Upgrade |
Other Unusual Items | 15.26 | 19.99 | 21.74 | 20.93 | 4.47 | 9.42 | Upgrade |
Pretax Income | 57.87 | 157.2 | 188.77 | 242.21 | 257.46 | 191.32 | Upgrade |
Income Tax Expense | -2.82 | 15.94 | 15.35 | 30.78 | 19.9 | 21.96 | Upgrade |
Earnings From Continuing Operations | 60.69 | 141.26 | 173.42 | 211.43 | 237.56 | 169.36 | Upgrade |
Minority Interest in Earnings | 39.28 | 47.9 | 29.04 | 28.2 | 6.39 | 0.52 | Upgrade |
Net Income | 99.98 | 189.17 | 202.47 | 239.62 | 243.95 | 169.88 | Upgrade |
Net Income to Common | 99.98 | 189.17 | 202.47 | 239.62 | 243.95 | 169.88 | Upgrade |
Net Income Growth | -49.86% | -6.57% | -15.51% | -1.77% | 43.60% | 52.93% | Upgrade |
Shares Outstanding (Basic) | 422 | 420 | 422 | 413 | 407 | 414 | Upgrade |
Shares Outstanding (Diluted) | 422 | 420 | 422 | 413 | 407 | 414 | Upgrade |
Shares Change (YoY) | -0.42% | -0.34% | 2.10% | 1.61% | -1.87% | 11.90% | Upgrade |
EPS (Basic) | 0.24 | 0.45 | 0.48 | 0.58 | 0.60 | 0.41 | Upgrade |
EPS (Diluted) | 0.24 | 0.45 | 0.48 | 0.58 | 0.60 | 0.41 | Upgrade |
EPS Growth | -49.65% | -6.25% | -17.24% | -3.33% | 46.34% | 36.67% | Upgrade |
Free Cash Flow | -184.89 | -11.64 | -209 | -415.47 | -733.59 | -199.84 | Upgrade |
Free Cash Flow Per Share | -0.44 | -0.03 | -0.49 | -1.01 | -1.80 | -0.48 | Upgrade |
Dividend Per Share | 0.096 | 0.096 | 0.096 | 0.114 | 0.120 | 0.084 | Upgrade |
Dividend Growth | - | - | -15.79% | -5.00% | 42.86% | 2.44% | Upgrade |
Gross Margin | 53.80% | 56.30% | 53.97% | 61.57% | 55.33% | 53.73% | Upgrade |
Operating Margin | 9.01% | 15.65% | 17.66% | 22.74% | 23.67% | 23.31% | Upgrade |
Profit Margin | 8.60% | 14.75% | 17.16% | 23.55% | 23.18% | 21.63% | Upgrade |
Free Cash Flow Margin | -15.91% | -0.91% | -17.72% | -40.84% | -69.71% | -25.45% | Upgrade |
EBITDA | 229.08 | 296.58 | 275.07 | 271.03 | 283.34 | 213.31 | Upgrade |
EBITDA Margin | 19.71% | 23.12% | 23.32% | 26.64% | 26.92% | 27.16% | Upgrade |
D&A For EBITDA | 124.35 | 95.82 | 66.83 | 39.65 | 34.18 | 30.2 | Upgrade |
EBIT | 104.73 | 200.76 | 208.24 | 231.38 | 249.16 | 183.11 | Upgrade |
EBIT Margin | 9.01% | 15.65% | 17.66% | 22.74% | 23.67% | 23.31% | Upgrade |
Effective Tax Rate | - | 10.14% | 8.13% | 12.71% | 7.73% | 11.48% | Upgrade |
Revenue as Reported | 1,162 | 1,283 | 1,180 | 1,017 | 1,052 | 785.38 | Upgrade |
Advertising Expenses | - | - | - | 0.52 | 1.01 | 1.32 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.